Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Martina S J McDermott"'
Autor:
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O’Leary, Frankie A Holmes, Virginia Espina, Lance A Liotta, Joyce O’Shaughnessy, Clair Gallagher, Lorraine O’Driscoll, Sweta Rani, Stephen F Madden, Neil A O’Brien, Charles Ginther, Dennis Slamon, Naomi Walsh, William M Gallagher, Radoslaw Zagozdzon, William R Watson, Norma O’Donovan, John Crown
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
Abstract Background Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of
Externí odkaz:
https://doaj.org/article/5de7181f330d45b98eeaa2bf7e64c819
Autor:
Martina S. J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/e0d45aa2e7a441378b538287bcf79ac3
Autor:
Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical
Externí odkaz:
https://doaj.org/article/2ebab795d742494f80b2463e971ee39c
Autor:
Amanda C. Sharko, Chang-Uk Lim, Martina S. J. McDermott, Chuck Hennes, Kingsavanh P. Philavong, Tiffanie Aiken, Victor V. Tatarskiy, Igor B. Roninson, Eugenia V. Broude
Publikováno v:
Cells, Vol 10, Iss 1, p 144 (2021)
Drug resistance is the main obstacle to achieving cures with both conventional and targeted anticancer drugs. The emergence of acquired drug resistance is initially mediated by non-genetic transcriptional changes, which occur at a much higher frequen
Externí odkaz:
https://doaj.org/article/c8a8be021b1e434fad24bdd39e2993bd
Autor:
Xiaokai Ding, Amanda C. Sharko, Martina S. J. McDermott, Gary P. Schools, Alexander Chumanevich, Hao Ji, Jing Li, Li Zhang, Zachary T. Mack, Vitali Sikirzhytski, Michael Shtutman, Laura Ivers, Norma O’Donovan, John Crown, Balázs Győrffy, Mengqian Chen, Igor B. Roninson, Eugenia V. Broude
Publikováno v:
Proceedings of the National Academy of Sciences. 119
Breast cancers (BrCas) that overexpress oncogenic tyrosine kinase receptor HER2 are treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase inhibitors (such as lapatinib). However, most patients with metastatic HER2+BrCa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640ca8c9a7646d6a2b9c98f13fb056ee
https://doi.org/10.1073/pnas.2201073119
https://doi.org/10.1073/pnas.2201073119